# A Continuation Protocol for Patients Previously Enrolled in a Study of Toca 511

> **NCT04327011** · PHASE1 · TERMINATED · sponsor: **Tocagen Inc.** · enrollment: 65 (actual)

## Conditions studied

- Glioblastoma Multiforme
- Astrocytoma
- Gliomas, Malignant

## Interventions

- **BIOLOGICAL:** Toca 511 vector
- **DRUG:** Toca FC • Flucytosine • 5-FC • 5-Fluorocytosine

## Key facts

- **NCT ID:** NCT04327011
- **Lead sponsor:** Tocagen Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2011-02
- **Primary completion:** 2019-12
- **Final completion:** 2019-12
- **Target enrollment:** 65 (ACTUAL)
- **Why stopped:** Sponsor decision
- **Last updated:** 2020-03-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04327011

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04327011, "A Continuation Protocol for Patients Previously Enrolled in a Study of Toca 511". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT04327011. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*